Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 14, 2017, the Board of Directors (the Board) of
Accelerate Diagnostics, Inc. (the Company) increased the size of
the Board to seven (7) members and elected Tom Brown as a
director of the Company, effective immediately. The Board has not
yet appointed Mr. Brown to any committees, though it may appoint
him to one or more committees in the future. On March 15, 2017,
the Company issued a press release announcing Mr. Browns
appointment to the board, a copy of which is attached hereto as
Exhibit 99.1 and is incorporated by reference.
Mr. Brown will receive the standard compensation for non-employee
directors as described in the Companys most recent proxy
statement on Schedule 14A dated April 1, 2016.
Except as described above, Mr. Brown was not selected as a
director of the Company to any arrangement or understanding
between him and any other person.
| Item 9.01 | Financial Statements and Exhibits |
(d)Exhibits.The following material is filed as an exhibit to this
Current Report on Form 8-K:
| Exhibit | ||
| Number | Description | |
| 99.1 | Press Release, dated March 15, 2017 |
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session down -0.27 at 22.93 with 301,767 shares trading hands.
